<DOC>
	<DOCNO>NCT02174289</DOCNO>
	<brief_summary>Cardiac resynchronisation therapy ( CRT ) establish treatment severe systolic heart failure well document benefit symptom improvement reduction morbidity mortality . However , upto 30 % patient respond treatment despite fulfil recommended indication . Lack clinical response may result imperfect leave ventricular lead placement vein around heart conventional technique . Optimum lead placement may constrain coronary venous anatomy may overlie scarred heart muscle may site late electrical depolarisation . In 10 % patient , conventional leave ventricular lead placement possible technical reason . Left ventricular endocardial lead placement may overcome limitation allow placement guide echocardiography , electrical mapping pattern heart muscle scar . We aim investigate target leave ventricular endocardial lead placement improve exercise capacity , heart failure symptom , heart function size , heart pump efficiency biochemical marker heart strain . Each parameter assess independently part composite cardiac performance score . Patients heart failure enrol require endocardial leave ventricular lead clinical ground either conventional leave ventricular lead implantation technically fail clinically non-responded CRT .</brief_summary>
	<brief_title>LV Endocardial Cardiac Resynchronisation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age great 18 year NYHA class IIIV LVEF ≤35 % QRS ≥120 milliseconds Optimal tolerate medical therapy Either unable position LV lead via standard coronary sinus CRT implantation OR Recipient CRTP CRTD system great 6 month standard indication AND limited improvement worsen clinical status despite device optimisation Informed consent Lifeexpectancy le 1 year due concomitant , noncardiovascular disorder Previous atrial septal defect device closure . Chronic renal dialysis End stage liver disease History stroke , myocardial infarction , unstable angina , Coronary artery bypass graft coronary stenting within last 3 month Presence correctable valvular disease ( aortic/mitral ) Mitral valve prosthesis . Contra indication vitamin K antagonist Unresolved intracardiac thrombus Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiac Resynchronisation Therapy</keyword>
	<keyword>Transseptal leave ventricular endocardial lead</keyword>
</DOC>